#Canada #Toronto #Clinical Trials #TriNetX #Genomic Data

Unlocking the Potential of Genomic and Real-World Data in Clinical Trials

In a world where the precision of clinical trials matters more than ever, a free upcoming webinar hosted by Xtalks promises to shed light on how harnessing connected real-world evidence, genomic and clinical data can significantly enhance clinical trial feasibility and site selection. This unique event aims to address the persistent challenges faced by researchers in accurately gauging patient availability, addressing a critical gap that often results in inefficiencies during the trial process.

The Importance of Accurate Feasibility Analysis

Clinical trial feasibility has historically suffered from the issue of outdated or inaccurate data. Traditional methods rely heavily on site surveys and historical enrollment statistics, both of which may not accurately reflect the current patient population that might enroll in future studies. Investigators often base their assessments on previous experiences, which do not account for the dynamic nature of patient demographics and genetic profiles.

In the upcoming webinar, industry experts Samantha Eells and Mark Hughes from TriNetX will demonstrate a groundbreaking approach to feasibility analysis that combines structured health data with genomic profiles and clinical notes. By leveraging these interconnected data sources, clinical operations teams can ensure that their protocols align with real patient populations, thus improving the chances of successful trial outcomes.

Bridging the Gap with Real-World Evidence

One of the innovative concepts discussed will be how to translate complex protocol eligibility criteria into actionable insights that can be queried across diverse real-world patient groups. Attendees will learn how to identify sites where both the target patient population and operational evidence support robust enrollment. This method is particularly essential for precision medicine studies, oncology trials, and programs addressing rare diseases, where eligibility cannot be solely determined by standard codes.

With a more integrated view of patients' health data, medical professionals can reduce enrollment risks significantly earlier in the study planning phase. This not only leads to more reliable feasibility estimates but also mitigates the likelihood of costly protocol amendments later on.

By utilizing a datas-layered approach, resources can be allocated more efficiently, focusing on locations that genuinely represent the patient cohort needed for the trial.

Transforming the Future of Clinical Trials

The insights shared during this session will equip clinical researchers with a practical framework for adopting evidence-driven feasibility assessments, steering their decisions based on confidence rather than assumptions. As the clinical research landscape evolves, embracing real-world evidence becomes crucial for the success of future studies.

Join Eells and Hughes for this live session scheduled for Wednesday, November 4, 2026, at 11 AM EST, where they will share how innovative data practices are setting a new standard for clinical trial feasibility.

To register for the webinar and learn more about how connected genomic and real-world data can transform clinical trials, visit Xtalks.

About Xtalks

Xtalks is a prominent platform dedicated to empowering professionals within the life sciences sector, including pharmaceutical, biotechnology, and healthcare industries, by providing them with trusted information and insightful collaboration opportunities. Their commitment to fostering informed decisions in a rapidly changing environment makes them a highly valued resource for many. Join their community to stay abreast of the latest developments in clinical research and more.

For additional information, please contact Soumya Shashikumar at +1 (416) 977-6555 x371 or via email at [email protected]